» Articles » PMID: 35958298

Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways

Overview
Publisher Sage Publications
Specialty Biology
Date 2022 Aug 12
PMID 35958298
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a hematological malignancy in which monoclonal plasma cells multiply in the bone marrow and monoclonal immunoglobulins are overproduced in older people. Several molecular and cytogenetic advances allow scientists to identify several genetic and chromosomal abnormalities that cause the disease. The comprehension of the pathophysiology of MM requires an understanding of the characteristics of malignant clones and the changes in the bone marrow microenvironment. This study aims to identify the central genes and to determine the key signaling pathways in MM by in silico approaches. A list of 114 differentially expressed genes (DEGs) is important in the prognosis of MM. The DEGs are collected from scientific publications and databases (https://www.ncbi.nlm.nih.gov/). These data are analyzed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) software (https://string-db.org/) through the construction of protein-protein interaction (PPI) networks and enrichment analysis of the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, by CytoHubba, AutoAnnotate, Bingo Apps plugins in Cytoscape software (https://cytoscape.org/) and by DAVID database (https://david.ncifcrf.gov/). The analysis of the results shows that there are 7 core genes, including , and . These top genes appear to play a role in the promotion and progression of MM. According to functional enrichment analysis, these genes are mainly involved in the following signaling pathways: Epstein-Barr virus infection, microRNA pathway, PI3K-Akt signaling pathway, and p53 signaling pathway. Several crucial genes, including TP53, MYC, CDND1, IL6, UBA52, EZH2, and MDM2, are significantly correlated with MM, which may exert their role in the onset and evolution of MM.

Citing Articles

The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.

Qin P, Huang H, Wang J, Jiang T, Zeng N, Wang Q Med Oncol. 2023; 40(9):276.

PMID: 37612479 DOI: 10.1007/s12032-023-02152-0.


The TT Genotype of the Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma.

Szudy-Szczyrek A, Mlak R, Mazurek M, Krajka T, Chocholska S, Bitkowska P Cells. 2023; 12(7).

PMID: 37048102 PMC: 10093279. DOI: 10.3390/cells12071029.

References
1.
Frassanito M, Desantis V, Di Marzo L, Craparotta I, Beltrame L, Marchini S . Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. J Pathol. 2018; 247(2):241-253. DOI: 10.1002/path.5187. View

2.
Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B . Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020; 25(9):e1406-e1413. PMC: 7485361. DOI: 10.1634/theoncologist.2020-0141. View

3.
Swaminathan B, Thorleifsson G, Joud M, Ali M, Johnsson E, Ajore R . Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015; 6:7213. PMC: 4455110. DOI: 10.1038/ncomms8213. View

4.
Alzrigat M, Jernberg-Wiklund H, Licht J . Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes. 2019; 2(3). PMC: 6370027. DOI: 10.3390/epigenomes2030016. View

5.
Wang F, Chen X, Yu X, Lin Q . Degradation of CCNB1 mediated by APC11 through UBA52 ubiquitination promotes cell cycle progression and proliferation of non-small cell lung cancer cells. Am J Transl Res. 2019; 11(11):7166-7185. PMC: 6895529. View